| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a … J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ... The Lancet 374 (9686), 301-314, 2009 | 2086 | 2009 |
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of … J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ... The Lancet 369 (9580), 2161-2170, 2007 | 1696 | 2007 |
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double … M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ... The lancet oncology 13 (1), 89-99, 2012 | 903 | 2012 |
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 635 | 2012 |
| Young adult sequelae of adolescent cannabis use: an integrative analysis E Silins, LJ Horwood, GC Patton, DM Fergusson, CA Olsson, ... The Lancet Psychiatry 1 (4), 286-293, 2014 | 588 | 2014 |
| Fall in human papillomavirus prevalence following a national vaccination program SN Tabrizi, JML Brotherton, JM Kaldor, SR Skinner, E Cummins, B Liu, ... The Journal of infectious diseases 206 (11), 1645-1651, 2012 | 368 | 2012 |
| Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study SN Tabrizi, JML Brotherton, JM Kaldor, SR Skinner, B Liu, D Bateson, ... The Lancet infectious diseases 14 (10), 958-966, 2014 | 362 | 2014 |
| Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials AR Kreimer, F Struyf, MR Del Rosario-Raymundo, A Hildesheim, ... The lancet oncology 16 (7), 775-786, 2015 | 361 | 2015 |
| Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double … SR Skinner, A Szarewski, B Romanowski, SM Garland, E Lazcano-Ponce, ... The Lancet 384 (9961), 2213-2227, 2014 | 226 | 2014 |
| Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind … CM Wheeler, SR Skinner, MR Del Rosario-Raymundo, SM Garland, ... The Lancet Infectious Diseases 16 (10), 1154-1168, 2016 | 223 | 2016 |
| Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study U Jaisamrarn, X Castellsague, SM Garland, P Naud, J Palmroth, ... PloS one 8 (11), e79260, 2013 | 202 | 2013 |
| Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination DA Machalek, SM Garland, JML Brotherton, D Bateson, K McNamee, ... The Journal of infectious diseases 217 (10), 1590-1600, 2018 | 184 | 2018 |
| Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study S Rachel Skinner, CM Wheeler, B Romanowski, X Castellsagué, ... International journal of cancer 138 (10), 2428-2438, 2016 | 178 | 2016 |
| Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 A Szarewski, WAJ Poppe, SR Skinner, CM Wheeler, J Paavonen, P Naud, ... International journal of cancer 131 (1), 106-116, 2012 | 178 | 2012 |
| Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial ER Bahmanyar, J Paavonen, P Naud, J Salmerón, SN Chow, D Apter, ... Gynecologic oncology 127 (3), 440-450, 2012 | 139 | 2012 |
| Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc … SM Garland, J Paavonen, U Jaisamrarn, P Naud, J Salmerón, SN Chow, ... International journal of cancer 139 (12), 2812-2826, 2016 | 138 | 2016 |
| Adolescent and young adult HPV vaccination in Australia: achievements and challenges SM Garland, SR Skinner, JML Brotherton Preventive medicine 53, S29-S35, 2011 | 131 | 2011 |
| Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the … D Apter, CM Wheeler, J Paavonen, X Castellsagué, SM Garland, ... Clinical and Vaccine Immunology 22 (4), 361-373, 2015 | 127 | 2015 |
| Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™) GJP Fernando, J Hickling, CMJ Flores, P Griffin, CD Anderson, ... Vaccine 36 (26), 3779-3788, 2018 | 122 | 2018 |
| Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy LN Lewis, DA Doherty, M Hickey, SR Skinner Contraception 81 (5), 421-426, 2010 | 117 | 2010 |
